Cargando…

Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada

BACKGROUND: Many patients with end-stage kidney disease (ESKD) do not appreciate how their survival may differ if treated with a kidney transplant compared with dialysis. A risk calculator (iChoose Kidney) developed and validated in the United States provides individualized mortality estimates for d...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Vivian S., Garg, Amit X., McArthur, Eric, Patzer, Rachel E., Gander, Jennifer, Roshanov, Pavel, Kim, S. Joseph, Knoll, Greg A., Yohanna, Seychelle, McCallum, Megan K., Naylor, Kyla L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172940/
https://www.ncbi.nlm.nih.gov/pubmed/30302267
http://dx.doi.org/10.1177/2054358118799693
_version_ 1783361045384921088
author Tan, Vivian S.
Garg, Amit X.
McArthur, Eric
Patzer, Rachel E.
Gander, Jennifer
Roshanov, Pavel
Kim, S. Joseph
Knoll, Greg A.
Yohanna, Seychelle
McCallum, Megan K.
Naylor, Kyla L.
author_facet Tan, Vivian S.
Garg, Amit X.
McArthur, Eric
Patzer, Rachel E.
Gander, Jennifer
Roshanov, Pavel
Kim, S. Joseph
Knoll, Greg A.
Yohanna, Seychelle
McCallum, Megan K.
Naylor, Kyla L.
author_sort Tan, Vivian S.
collection PubMed
description BACKGROUND: Many patients with end-stage kidney disease (ESKD) do not appreciate how their survival may differ if treated with a kidney transplant compared with dialysis. A risk calculator (iChoose Kidney) developed and validated in the United States provides individualized mortality estimates for different treatment options (dialysis vs living or deceased donor kidney transplantation). The calculator can be used with patients and families to help patients make more educated treatment decisions. OBJECTIVE: To validate the iChoose Kidney risk calculator in Ontario, Canada. DESIGN: External validation study. SETTING: We used several linked administrative health care databases from Ontario, Canada. PATIENTS: We included 22 520 maintenance dialysis patients and 4505 kidney transplant recipients. Patients entered the cohort between 2004 and 2014. MEASUREMENTS: Three-year all-cause mortality. METHODS: We assessed model discrimination using the C-statistic. We assessed model calibration by comparing the observed versus predicted mortality risk and by using smoothed calibration plots. We used multivariable logistic regression modeling to recalibrate model intercepts using a correction factor, when appropriate. RESULTS: In our final version of the iChoose Kidney model, we included the following variables: age (18-80 years), sex (male, female), race (white, black, other), time on dialysis (<6 months, 6-12 months, >12 months), and patient comorbidities (hypertension, diabetes, and/or cardiovascular disease). Over the 3-year follow-up period, 33.3% of dialysis patients and 6.2% of kidney transplant recipients died. The discriminatory ability was moderate (C-statistic for dialysis: 0.70, 95% confidence interval [CI]: 0.69-0.70, and C-statistic for transplant: 0.72, 95% CI: 0.69-0.75). The 3-year observed and predicted mortality estimates were comparable and even more so after we recalibrated the intercepts in 2 of our models (dialysis and deceased donor kidney transplantation). As done in the United States, we developed a Canadian Web site and an iOS application called Dialysis vs. Kidney Transplant- Estimated Survival in Ontario. LIMITATIONS: Missing data in our databases precluded the inclusion of all variables that were in the original iChoose Kidney (ie, patient ethnicity and low albumin). We were unable to perform all preplanned analyses due to the limited sample size. CONCLUSIONS: The original iChoose Kidney risk calculator was able to adequately predict mortality in this Canadian (Ontario) cohort of ESKD patients. After minor modifications, the predictive accuracy improved. The Dialysis vs. Kidney Transplant- Estimated Survival in Ontario risk calculator may be a valuable resource to help ESKD patients make an informed decision on pursuing kidney transplantation.
format Online
Article
Text
id pubmed-6172940
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61729402018-10-09 Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada Tan, Vivian S. Garg, Amit X. McArthur, Eric Patzer, Rachel E. Gander, Jennifer Roshanov, Pavel Kim, S. Joseph Knoll, Greg A. Yohanna, Seychelle McCallum, Megan K. Naylor, Kyla L. Can J Kidney Health Dis Original Research Article BACKGROUND: Many patients with end-stage kidney disease (ESKD) do not appreciate how their survival may differ if treated with a kidney transplant compared with dialysis. A risk calculator (iChoose Kidney) developed and validated in the United States provides individualized mortality estimates for different treatment options (dialysis vs living or deceased donor kidney transplantation). The calculator can be used with patients and families to help patients make more educated treatment decisions. OBJECTIVE: To validate the iChoose Kidney risk calculator in Ontario, Canada. DESIGN: External validation study. SETTING: We used several linked administrative health care databases from Ontario, Canada. PATIENTS: We included 22 520 maintenance dialysis patients and 4505 kidney transplant recipients. Patients entered the cohort between 2004 and 2014. MEASUREMENTS: Three-year all-cause mortality. METHODS: We assessed model discrimination using the C-statistic. We assessed model calibration by comparing the observed versus predicted mortality risk and by using smoothed calibration plots. We used multivariable logistic regression modeling to recalibrate model intercepts using a correction factor, when appropriate. RESULTS: In our final version of the iChoose Kidney model, we included the following variables: age (18-80 years), sex (male, female), race (white, black, other), time on dialysis (<6 months, 6-12 months, >12 months), and patient comorbidities (hypertension, diabetes, and/or cardiovascular disease). Over the 3-year follow-up period, 33.3% of dialysis patients and 6.2% of kidney transplant recipients died. The discriminatory ability was moderate (C-statistic for dialysis: 0.70, 95% confidence interval [CI]: 0.69-0.70, and C-statistic for transplant: 0.72, 95% CI: 0.69-0.75). The 3-year observed and predicted mortality estimates were comparable and even more so after we recalibrated the intercepts in 2 of our models (dialysis and deceased donor kidney transplantation). As done in the United States, we developed a Canadian Web site and an iOS application called Dialysis vs. Kidney Transplant- Estimated Survival in Ontario. LIMITATIONS: Missing data in our databases precluded the inclusion of all variables that were in the original iChoose Kidney (ie, patient ethnicity and low albumin). We were unable to perform all preplanned analyses due to the limited sample size. CONCLUSIONS: The original iChoose Kidney risk calculator was able to adequately predict mortality in this Canadian (Ontario) cohort of ESKD patients. After minor modifications, the predictive accuracy improved. The Dialysis vs. Kidney Transplant- Estimated Survival in Ontario risk calculator may be a valuable resource to help ESKD patients make an informed decision on pursuing kidney transplantation. SAGE Publications 2018-10-04 /pmc/articles/PMC6172940/ /pubmed/30302267 http://dx.doi.org/10.1177/2054358118799693 Text en © The Author(s) 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Tan, Vivian S.
Garg, Amit X.
McArthur, Eric
Patzer, Rachel E.
Gander, Jennifer
Roshanov, Pavel
Kim, S. Joseph
Knoll, Greg A.
Yohanna, Seychelle
McCallum, Megan K.
Naylor, Kyla L.
Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada
title Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada
title_full Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada
title_fullStr Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada
title_full_unstemmed Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada
title_short Predicting 3-Year Survival in Patients Receiving Maintenance Dialysis: An External Validation of iChoose Kidney in Ontario, Canada
title_sort predicting 3-year survival in patients receiving maintenance dialysis: an external validation of ichoose kidney in ontario, canada
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172940/
https://www.ncbi.nlm.nih.gov/pubmed/30302267
http://dx.doi.org/10.1177/2054358118799693
work_keys_str_mv AT tanvivians predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT gargamitx predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT mcarthureric predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT patzerrachele predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT ganderjennifer predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT roshanovpavel predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT kimsjoseph predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT knollgrega predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT yohannaseychelle predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT mccallummegank predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada
AT naylorkylal predicting3yearsurvivalinpatientsreceivingmaintenancedialysisanexternalvalidationofichoosekidneyinontariocanada